Alexandra Collingbourne Alexandra Collingbourne

VividQ opening US office after taking funding haul past $30m

Cambridge DeepTech innovator VividQ is expanding in the United States on the wings of fresh funding success. VividQ, a leader in computational holography, has secured an extra $7.5 million Series A funding, bringing its total haul to more than $30m.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Abselion announces £1.1m project to develop next-gen cell platform for viral vector production

Biotechnology companies and research organisations in the UK and Canada are entering into a R&D project jointly funded by a 1.1 million GBP grant from Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project is led by VVector Bio and joined by the NRC, Revvity and Abselion.


Read More
Alexandra Collingbourne Alexandra Collingbourne

Rovco joins Global Wind Energy Council

Rovco, a leader in tech-driven offshore wind solutions, has joined global industry group the Global Wind Energy Council (GWEC). In joining GWEC, Rovco becomes part of a leading community of more than 1,500 companies across 80 countries, collaborating to create a better global policy environment for wind power.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Interview with Rovco CEO: New technologies can close huge offshore wind skills gap

New technologies have the ability to massively close the huge skills gap and shortage of workers that is looming over the offshore wind industry, allowing 10 to 17 times more work to be done by one person, according to Brian Allen, CEO of Rovco, a UK company focused on automating offshore wind services by creating and deploying novel tech solutions.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Rovco secures contract for Green Volt floater

Rovco has been awarded the site characterisation operations for the Green Volt floating offshore wind farm, situated 80 km east of Peterhead, Scotland. Slated to be fully operational by 2029, Green Volt is poised to become one of the world's largest floating offshore wind farms.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Oxford Drug Design makes key appointment

Oxford Drug Design, an Oxford-based AI drug discovery company and pioneer in AI therapeutic innovation, has appointed leading oncologist and academic Professor Sarah Blagden to its Scientific Advisory Board.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Barcode-Less Product Scanners

SeeChange Technologies, a company known for its retail-focused computer vision AI technology, has announced a strategic partnership with Diebold Nixdorf, a global leader in retail consumer and staff journey solutions, to introduce an innovative series of AI-powered self-checkout solutions.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Cambridge Nutraceuticals builds brand portfolio with acquisition of GP Nutrition

Cambridge Nutraceuticals, the parent company of science-backed nutritional food supplement brands, FutureYou Cambridge and Prime Fifty, has expanded its brand portfolio with the acquisition of GP Nutrition. GP Nutrition was founded by leading nutritionist and double Sunday Times bestselling author, Gabriela Peacock.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Psyomics secures £4M to revolutionise mental health assessment with AI

Psyomics, a UK-based mental health technology company, has secured £4 million in fresh funding. Parkwalk Advisors (which invested in adsilico and Oxford Endovascular) the UK’s most active investor in university spinouts, led the funding round by investing a further £3.5 million.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect®PLUS. In conjunction with the Company’s Cyto-Mine® platform, the new assay provides a streamlined method to measure antibody production in single cells by rapidly detecting secreted human IgG, enabling the identification and selection of cells with the highest productivity for more efficient cell line development.

Read More